Trial intelligence / Profile preview

Epirubicin as second-line treatment in TOP2A-amplified, oxaliplatin-refractory metastatic colorectal cancer

2013-001648-79Phase 2Completed

Sponsor: University Hospital Odense
Start: Jul 2013
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of epirubicin in colorectal cancer (CRC), sponsored by University Hospital Odense. Primary endpoint: Progression-free survival. Started Jul 2013; status: completed.

Drugs

epirubicin

Conditions

colorectal cancer (CRC)

Beyond the preview

Go deeper on 2013-001648-79.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-001648-79.